| ArticlePedia |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
ArticlePedia - Volatile Oil
The Light Crude Continuous Contract fell from $67.70 a barrel on Monday to $62.75 on Thursday, and closed at $ According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product 65.79 on Friday. Consequently, oil stocks followed the sharp move in oil prices last week. The first chart is ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in an OIH (basket of oil stocks) daily chart, which suggests a consolidation or correction over the next few wee lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ks. The Price-by-Volume bar (on left side of chart) indicates OIH may trade between 111 and 114 short-term. Th here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ere's also resistance around 115, i.e. the 10 & 20 day MAs. There's further resistance at 117.88, which is the d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro current Parabolic SAR sell signal (red dots). However, if oil tests $70 a barrel, then the high at 119.30 is ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc another barrier. Oil is less than $5 a barrel below $70. So, OIH may rise and fall quickly. OIH major support easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi is at the (rising) 50 day MA, currently just over 108. However, if OIH closes below the 50 day MA, then next nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically major support is around 105, i.e. the longer Price-by-Volume bar. Around 105 may be the bottom of the consolid and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ation zone, while a correction may result somewhere in the 90s or 80s. The short-term price of oil is largely ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi dependent on the rate of global economic growth, reflected in monthly economic data, and supply disruptions, i ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ncluding geopolitical events and hurricanes in the Gulf. The second chart is an SPX (S&P 500) same period dai dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ly chart. SPX lead OIH higher and then lower recently. If OIH continues to lag SPX, then OIH will rise next we cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ek, perhaps to the Parabolic SAR sell signal, trade around the 10 & 20 day MAs, and then fall to a new recent tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen low, e.g. 105. SPX created a bullish doji at the 50 day MA. However, a volatile trading range may continue nex t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel t week, perhaps between 1,200 and 1,235. Next week is a light economic data week: Mon: None, Tue: Existing Ho ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust me Sales, Wed: Durable Goods Orders and New Home Sales, Thu: Unemployment Claims, and Fri: Revised Michigan Co y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products nsumer Sentiment. The weekly oil inventory report is Wed at 10:30 AM ET. There are several other excellent tra . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ding opportunities next week, where large gains can be made quickly. "Chance favors the prepared mind"-Louis P elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:High School Fund Raising Made Easy Making Your Purpose Your Business Step #2- Getting From Point A to Point B Google Catalogs - Old Gashioned Mail Order Meets High Tech Search
|